By James Whitmore, Clayton Hirst, James Whitmore Clayton Hirst5 March 1999
The prospect of a huge £6bn property company dominating the central London office market would be mouth-watering for investors, who are starved of a property equivalent to BP Amoco or GlaxoWellcome.
You must be logged in to continue
Register for free to finish this article.
Sign up now for the following benefits:
To access this article REGISTER NOW
Would you like print copies, app and digital replica access too? SUBSCRIBE for as little as £5 per week.